The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Moderna shot to prominence near the end of 2021 ... voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA ...